KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Equity Average (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Equity Average for 12 consecutive years, with $570.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 26.5% to $570.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $570.6 million, a 26.5% decrease, with the full-year FY2025 number at $668.3 million, down 20.57% from a year prior.
  • Equity Average was $570.6 million for Q4 2025 at Xenon Pharmaceuticals, down from $596.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $907.8 million in Q1 2024 to a low of $223.8 million in Q1 2021.
  • A 5-year average of $629.5 million and a median of $667.8 million in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: skyrocketed 204.18% in 2022, then decreased 27.31% in 2025.
  • Xenon Pharmaceuticals' Equity Average stood at $399.5 million in 2021, then soared by 84.56% to $737.3 million in 2022, then increased by 6.1% to $782.3 million in 2023, then dropped by 0.75% to $776.4 million in 2024, then dropped by 26.5% to $570.6 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Equity Average are $570.6 million (Q4 2025), $596.7 million (Q3 2025), and $669.0 million (Q2 2025).